Predicting Immunotherapy Response and Survival of Lung Cancer Patients Using Artificial Intelligence and Radiomics (Radiology-AI-Lung)

Huazhong University of Science and Technology

Status: Enrolling

Conditions: Lung Cancer (Diagnosis)

Study type: Observational

Funder types: Other

Identifiers

NCT07059923

2025-0584

Details and patient eligibility

About

CT imaging data from lung cancer (NSCLC and SCLC) patients prior to the initiation of immunotherapy (and possibly also after treatment) will be collected. The processing pipeline includes automatic tumor segmentation, radiomics feature extraction, feature selection, and construction of a classification model.

Enrollment: 400 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Patients were treated for lung cancer in Wuhan Union Hospital from July 2025 to July 2026;
2. Aged > 18 years old;
3. At least one CT scan before treatment;
4. Tissue biopsy pathological examination confirmed the diagnosis of the above tumors.

Exclusion criteria

1. Poor image quality;
2. Incomplete clinical data or loss of follow-up;
3. Presence of another primary malignancy other than lung cancer;
4. Unclear pathological diagnosis.